Log In Get Started
Press Releases May 4, 2026 04:15 PM

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

AnaptysBio CEO to Feature in H.C. Wainwright Royalty Company Virtual Conference Fireside Chat

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
ANAB

AnaptysBio, a Nasdaq-listed biotechnology company, announced that its president and CEO, Daniel Faga, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference. The company's main focus is managing financial collaborations related to its drug royalties, notably Jemperli with GSK and imsidolimab with Vanda, aiming to protect and maximize shareholder value from these royalty streams.

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
ANAB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • AnaptysBio manages royalty financial collaborations for key drug candidates Jemperli with GSK and imsidolimab with Vanda.
  • The CEO's participation in the virtual conference highlights the company’s focus on transparency and engagement with investors regarding its royalty business.
  • The company’s strategy centers on protecting and returning value from its royalties to shareholders.

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 1:30pm ET.

To register for the conference, please visit https://hcwevents.com/royalty-company-conference.

About Anaptys

Anaptys manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.

Contact:
Anaptys Investor Relations
investors@anaptysbio.com


Risks

  • The company's financial success heavily depends on the commercial performance of licensed drugs, introducing market and clinical risks that could affect royalty income.
  • Collaborations with larger pharmaceutical firms like GSK and Vanda might carry uncertainties around partnership terms and regulatory approvals impacting future revenues.
  • The biotechnology and pharmaceutical sectors remain highly sensitive to clinical trial outcomes, regulatory decisions, and market adoption, which may create volatility in royalty-based revenues.

More from Press Releases

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress Jun 14, 2026 Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026